Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2006 |
| Outros Autores: | , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da UFBA |
| Texto Completo: | http://www.repositorio.ufba.br/ri/handle/ri/6946 |
Resumo: | p.11-16 |
| id |
UFBA-2_deca7f2ecf753ac22252fe266be5948d |
|---|---|
| oai_identifier_str |
oai:repositorio.ufba.br:ri/6946 |
| network_acronym_str |
UFBA-2 |
| network_name_str |
Repositório Institucional da UFBA |
| repository_id_str |
1932 |
| spelling |
Parise, E.Cheinquer, H.Crespo, D.Meirelles, A.Martinelli, A.Sette, H.Gallizi, J.Silva, R.Lacet, C.Correa, E.Cotrim, Helma PinchemelFonseca, J.Paraná, RaymundoSpinelli, V.Amorim, Welma WildesTatsch, FernandoPessoa, M.Parise, E.Cheinquer, H.Crespo, D.Meirelles, A.Martinelli, A.Sette, H.Gallizi, J.Silva, R.Lacet, C.Correa, E.Cotrim, Helma PinchemelFonseca, J.Paraná, RaymundoSpinelli, V.Amorim, Welma WildesTatsch, FernandoPessoa, M.2012-10-15T18:34:28Z2012-10-15T18:34:28Z2006-021413-8670http://www.repositorio.ufba.br/ri/handle/ri/6946v. 10, n. 1p.11-16Peginterferon alfa plus ribavirin is currently the treatment of choice for chronic hepatitis C. Peginterferon alfa-2a (40KD) plus ribavirin has given an overall sustained virological response of 18% in F3/F4 previous nonresponder US patients. We evaluated the effectiveness of peginterferon alfa-2a (40KD) plus ribavirin in Brazilian patients who were relapsers or nonresponders to previous interferon-based therapy. One-hundred-thirty-four patients with biopsy-proven chronic hepatitis C, HCV RNA positive, elevated ALT and who were either relapsers (n=37) or nonresponders (n=97) to at least 24 weeks of conventional interferon/ribavirin therapy were retreated with peginterferon alfa-2a (40KD) 180mg/qw and ribavirin 800mg bid for 48 weeks. Efficacy was assessed as virological response (defined as undetectable HCV RNA) at the end of treatment (EoT) and at the end of follow-up (SVR - Sustained Virological Response). Safety assessments consisted of clinical and laboratory evaluations. In the patient sample, 72% were genotype 1 and 34% were cirrhotic. In an intention-to-treat analysis, relapser patients showed 78% EoT response and 51% SVR. Nonresponders showed 57% EoT response and 26% SVR. Positive predictive factors of SVR were non-1 genotype and relapser state. Six percent of the patients interrupted treatment because of adverse events and 45% had dose reduction (mainly associated with leucopenia and anemia). Brazilian patient relapsers and nonresponders to conventional interferon and ribavirin treatment can achieve a sustained virological response when retreated with peginterferon alfa-2a (40KD) and ribavirin. The safety profile is similar to that of naive patients.Submitted by Texeira Ana (atanateixeira@gmail.com) on 2012-10-15T18:34:28Z No. of bitstreams: 1 Parise, E..pdf: 577473 bytes, checksum: e51e0dc9a8014dbbd6c8612bd8775dad (MD5)Made available in DSpace on 2012-10-15T18:34:28Z (GMT). No. of bitstreams: 1 Parise, E..pdf: 577473 bytes, checksum: e51e0dc9a8014dbbd6c8612bd8775dad (MD5) Previous issue date: 2006-02SalvadorThe Brazilian Journal of Infectious Diseases and Contexto Publishinghttp://dx.doi.org/10.1590/S1413-86702006000100003reponame:Repositório Institucional da UFBAinstname:Universidade Federal da Bahia (UFBA)instacron:UFBAPeginterferon alfaRibavirinHepatitis CSafetyEfficacyPeginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapyBrazilian Journal of Infectious Diseasesinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleenginfo:eu-repo/semantics/openAccessORIGINALParise, E..pdfParise, E..pdfapplication/pdf577473https://repositorio.ufba.br/bitstream/ri/6946/1/Parise%2c%20E..pdfe51e0dc9a8014dbbd6c8612bd8775dadMD51LICENSElicense.txtlicense.txttext/plain1809https://repositorio.ufba.br/bitstream/ri/6946/2/license.txt8bb3e3eb871f5854a9ec419f68651b60MD52TEXTParise, E..pdf.txtParise, E..pdf.txtExtracted texttext/plain26382https://repositorio.ufba.br/bitstream/ri/6946/3/Parise%2c%20E..pdf.txt10b0c2093d445f0f4698b0fa65b6480bMD53ri/69462022-07-05 14:03:10.594oai:repositorio.ufba.br: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ório InstitucionalPUBhttp://192.188.11.11:8080/oai/requestopendoar:19322022-07-05T17:03:10Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)false |
| dc.title.pt_BR.fl_str_mv |
Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy |
| dc.title.alternative.pt_BR.fl_str_mv |
Brazilian Journal of Infectious Diseases |
| title |
Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy |
| spellingShingle |
Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy Parise, E. Peginterferon alfa Ribavirin Hepatitis C Safety Efficacy |
| title_short |
Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy |
| title_full |
Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy |
| title_fullStr |
Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy |
| title_full_unstemmed |
Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy |
| title_sort |
Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy |
| author |
Parise, E. |
| author_facet |
Parise, E. Cheinquer, H. Crespo, D. Meirelles, A. Martinelli, A. Sette, H. Gallizi, J. Silva, R. Lacet, C. Correa, E. Cotrim, Helma Pinchemel Fonseca, J. Paraná, Raymundo Spinelli, V. Amorim, Welma Wildes Tatsch, Fernando Pessoa, M. |
| author_role |
author |
| author2 |
Cheinquer, H. Crespo, D. Meirelles, A. Martinelli, A. Sette, H. Gallizi, J. Silva, R. Lacet, C. Correa, E. Cotrim, Helma Pinchemel Fonseca, J. Paraná, Raymundo Spinelli, V. Amorim, Welma Wildes Tatsch, Fernando Pessoa, M. |
| author2_role |
author author author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Parise, E. Cheinquer, H. Crespo, D. Meirelles, A. Martinelli, A. Sette, H. Gallizi, J. Silva, R. Lacet, C. Correa, E. Cotrim, Helma Pinchemel Fonseca, J. Paraná, Raymundo Spinelli, V. Amorim, Welma Wildes Tatsch, Fernando Pessoa, M. Parise, E. Cheinquer, H. Crespo, D. Meirelles, A. Martinelli, A. Sette, H. Gallizi, J. Silva, R. Lacet, C. Correa, E. Cotrim, Helma Pinchemel Fonseca, J. Paraná, Raymundo Spinelli, V. Amorim, Welma Wildes Tatsch, Fernando Pessoa, M. |
| dc.subject.por.fl_str_mv |
Peginterferon alfa Ribavirin Hepatitis C Safety Efficacy |
| topic |
Peginterferon alfa Ribavirin Hepatitis C Safety Efficacy |
| description |
p.11-16 |
| publishDate |
2006 |
| dc.date.issued.fl_str_mv |
2006-02 |
| dc.date.accessioned.fl_str_mv |
2012-10-15T18:34:28Z |
| dc.date.available.fl_str_mv |
2012-10-15T18:34:28Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://www.repositorio.ufba.br/ri/handle/ri/6946 |
| dc.identifier.issn.none.fl_str_mv |
1413-8670 |
| dc.identifier.number.pt_BR.fl_str_mv |
v. 10, n. 1 |
| identifier_str_mv |
1413-8670 v. 10, n. 1 |
| url |
http://www.repositorio.ufba.br/ri/handle/ri/6946 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
The Brazilian Journal of Infectious Diseases and Contexto Publishing |
| publisher.none.fl_str_mv |
The Brazilian Journal of Infectious Diseases and Contexto Publishing |
| dc.source.pt_BR.fl_str_mv |
http://dx.doi.org/10.1590/S1413-86702006000100003 |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFBA instname:Universidade Federal da Bahia (UFBA) instacron:UFBA |
| instname_str |
Universidade Federal da Bahia (UFBA) |
| instacron_str |
UFBA |
| institution |
UFBA |
| reponame_str |
Repositório Institucional da UFBA |
| collection |
Repositório Institucional da UFBA |
| bitstream.url.fl_str_mv |
https://repositorio.ufba.br/bitstream/ri/6946/1/Parise%2c%20E..pdf https://repositorio.ufba.br/bitstream/ri/6946/2/license.txt https://repositorio.ufba.br/bitstream/ri/6946/3/Parise%2c%20E..pdf.txt |
| bitstream.checksum.fl_str_mv |
e51e0dc9a8014dbbd6c8612bd8775dad 8bb3e3eb871f5854a9ec419f68651b60 10b0c2093d445f0f4698b0fa65b6480b |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA) |
| repository.mail.fl_str_mv |
|
| _version_ |
1808459407685582848 |